BMI ≥35.0 kg/m2 with comorbidities or BMI≥40 Stable body weight (less than 5 kg self-reported change during the previous 3 months) Informed consent obtained before any trial-related activity takes place Exclusion criteria Stage 3-5 CKD (GFR<60 ml/min) Type 1 diabetes Uncontrolled type 2 diabetes Previous infection with SARS CoV-2 Immunodeficiency or immunomodulating treatment Treatment with anti-obesity medications or other medications potentially affecting body weight or SGLT2 inhibitors Pregnancy and lactation Previous gout episodes Cardio and cerebrovascular accidents in the preceding 12 months